Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

NCT01303172 is registered in ClinicalTrials.gov with Immodulon Therapeutics Ltd as lead sponsor.

NCT NCT01303172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01303172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer
Lead sponsor
Immodulon Therapeutics Ltd
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
January 31, 2016
Enrollment
110 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic cancer